



### **ROBIN ROBINSON, PhD**

Dr. Robin Robinson was appointed in April 2008 as the first director of the Biomedical Advanced Research and Development Authority (BARDA), and Deputy Assistant Secretary in the Office of the Assistant Secretary for Preparedness and Response within HHS.

Dr. Robinson previously served from 2004-2008 as the Director for the Influenza & Emerging Disease Program within BARDA and its predecessor agency at HHS. Dr. Robinson was recruited by HHS from the vaccine industry in May 2004 to establish a program with scientific and technical experts to implement the strategic plans and policies for medical countermeasures outlined in the *National Strategy for Pandemic Influenza*. These measures included development, acquisition and establishment of national medical countermeasure stockpiles, and expansion of domestic manufacturing surge capacities for influenza vaccines, antiviral drugs, rapid diagnostics, and non-pharmaceutical countermeasures including respiratory devices. For his leadership in this role, Dr. Robinson was the recipient of the Department of Defense's Clay Dalrymple Award in 2008 and a finalist for the Service to America Medal in 2009.

Dr. Robinson received a Bachelor's degree in Biology from Millsaps College in 1976, a Doctoral degree from the University of Mississippi Medical School in medical microbiology, and completed in 1983 a NIH postdoctoral fellowship with the State University of New York at Stony Brook in molecular oncology. As Director of Vaccines at Novavax, Inc., he developed patented platform vaccine technologies including virus-like particles and subunit protein vaccines for human pathogens including malaria, human papilloma, hepatitis, and influenza and for prostate, melanoma, and cervical cancers. Dr. Robinson also serves on World Health Organization (WHO) international expert teams on pandemic influenza vaccines. Additionally, he continues to serve as an editorial board member and reviewer for several professional scientific and technical journals on virology, vaccines, public health, and biotechnology.